Rep. Mike Gallagher

The bill directs the Joint Committee on the Library to remove the bust of Roger Brooke Taney in the Old Supreme Court Chamber of the Capitol and to obtain a bust of Clarence Thomas with which to replace it.

United States and Republic of Korea Alliance Support Act This bill prohibits the Department of Defense (DOD) from reducing below 22,000 the number of active-duty service members deployed to South Korea unless DOD makes specified reports and certifications, including that such a reduction is in the interest of national security.

Arctic Security Initiative Act of 2021 This bill requires the Department of Defense (DOD) to conduct an assessment and implement a program related to national security interests in the Arctic region. Specifically, the Commander of the United States Northern Command of DOD must consult and coordinate with specified defense entities to conduct an independent assessment with respect to the activities and resources required for FY2023-FY2027 to achieve specified objectives related to national security interests in the Arctic region. The assessment must focus on the activities and resources required to achieve the following objectives: the implementation of the National Defense Strategy and military service-specific strategies with respect to the Arctic region; the maintenance or restoration of the comparative military advantage of the United States in response to great power competitors in the Arctic region; the reduction of the risk of executing operation and contingency plans of DOD; and to maximize execution of DOD operation and contingency plans, in the event deterrence fails. Additionally, DOD must establish the Arctic Security Initiative program to enhance security in the Arctic region, to be informed by the assessment required by this bill. DOD must annually submit an unclassified future years plan, which may include a classified annex, for the activities and resources of the program that includes specified elements (e.g., a detailed time line for achieving requirements). The plan must also be included in budget materials submitted by DOD in support of the budget of the President for FY2023.

Foreign Gain-of-Function Research Prevention Act of 2021 This bill prohibits the use of federal funds to conduct or support gain-of-function research involving potential pandemic pathogens by China, Russia, Iran, North Korea, or other foreign adversaries. Gain-of-function research is any research that is anticipated to confer an attribute on a pathogen to enhance its pathogenicity or transmissibility in mammals. If the Department of State finds that an entity has used funds for prohibited research, the entity may not receive any federal funding for a period of five years.

This bill requires the Department of Veterans Affairs to ensure that, if it creates a presumption of service-connection between the occurrence of a disease and exposure to an herbicide agent while serving in the Armed Forces between January 9, 1962, and June 30, 1976, at a military base in Thailand, such presumption must also apply to exposure at any military base in Thailand, regardless of where on the base the veteran was located or what military job specialty the veteran performed.

Taiwan Defense Act of 2021 This bill establishes that it shall be U.S. policy to maintain the ability of the U.S. Armed Forces to defeat attempts by China to invade and seize control of Taiwan before U.S. forces can respond effectively.

This resolution expresses support for the goals and ideals of PCOS Awareness Month. Polycystic ovary syndrome (PCOS) is caused by a hormone imbalance. Symptoms can include infertility, weight gain, excess hair growth, and acne.

Codifying Useful Regulatory Definitions Act or the CURD Act This bill provides statutory authority for a definition of natural cheese . Under the bill, natural cheese is defined as cheese that is produced from animal milk or certain dairy ingredients and is produced in accordance with established cheese-making standards.

No Vax Pass Act of 2021 This bill generally prohibits states and localities from expending COVID-19 relief funds on systems (other than in health care contexts) that verify an individual's COVID-19 vaccination status. However, the bill provides an exception for state educational agencies, local educational agencies, institutions of higher education, secondary schools, and elementary schools. These entities may implement a system to verify the COVID-19 vaccination status of students and staff provided that requirements for COVID-19 vaccines are no stricter than requirements for any other vaccine.

Promising Pathway Act This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable. The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations. During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis. The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties. A provisionally approved drug must be labeled as such. If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded. The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective. Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.